GEN obtains approval from the BEBO Basis for Part II PD examine
GEN Prescription drugs has acquired approval from the BEBO Basis for the Moral Assessment of Biomedical Analysis to provoke a Part II medical trial within the Netherlands of its novel drug, SUL-238, for mitochondrial dysfunction in sufferers with Parkinson’s illness (PD).
The approval permits the corporate to activate its medical website in Groningen, with affected person enrollment beginning in April 2026.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
The Part II proof-of-concept examine, SHEPHERD, is a single-center, randomized, double-blind, placebo-controlled trial.
It can assess the consequences of SUL-238 on high-energy phosphates utilizing magnetic resonance spectroscopy (31P-MRS) in sufferers identified with untreated early-stage Parkinson’s.
The first purpose of the examine is to guage how SUL-238 works via MRS scans, which work equally to magnetic resonance imaging (MRI) scans. The examine can even look at the security profile of SUL-238.
Researchers will consider whether or not SUL-238 improves mitochondrial perform in sufferers with Parkinson’s illness by evaluating it to a placebo.
Individuals take SUL-238 or a placebo each day for a interval of 28 days. They may go to clinics each two weeks for routine checks and testing throughout therapy and once more 28 days after their final dose.
Every participant retains a symptom diary and information their oral consumption of SUL-238.
Abidin Gülmüş, Chairman of GEN Prescription drugs, mentioned: “Following the moral approval, we sit up for the beginning of affected person enrollment within the Netherlands. This part II examine might be one other necessary milestone in the direction of tackling neurodegenerative ailments on the organic foundation.”
SUL-238 is a hibernation-inspired small molecule that targets mitochondria. The compound helps mitochondrial bioenergetics through complicated I/IV activation and improves mitochondrial perform in varied preclinical fashions of cardiovascular, renal and neurodegenerative ailments.
GEN licenses SUL-238 from Sulfateq for purposes in neurodegenerative ailments.
